EGFR and neoplasm: Our laboratory and others have previously demonstrated a role for the chemokine interleukin-8 (IL-8, CXCL8) in mechanisms of tumor progression in several tumor types, including as a driver of resistance to chemotherapy [6], EGFR-targeted therapy [7], and immunotherapy [8–11].